Synergism between clofarabine and decitabine through p53R2

A pharmacodynamic drug-drug interaction modeling

Karen E. Thudium, Sampa Ghoshal, Gerald J. Fetterly, Jason P Den Haese, Adam R Karpf, Meir Wetzler

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.

Original languageEnglish (US)
Pages (from-to)1410-1416
Number of pages7
JournalLeukemia Research
Volume36
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

decitabine
Drug Design
Drug Interactions
Acute Myeloid Leukemia
Pharmaceutical Preparations
Purine Nucleosides
Myeloid Cells
Clinical Trials
Cell Line
Messenger RNA
clofarabine

Keywords

  • AML
  • Clofarabine
  • Decitabine
  • Pharmacodynamic modeling
  • Synergy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Synergism between clofarabine and decitabine through p53R2 : A pharmacodynamic drug-drug interaction modeling. / Thudium, Karen E.; Ghoshal, Sampa; Fetterly, Gerald J.; Haese, Jason P Den; Karpf, Adam R; Wetzler, Meir.

In: Leukemia Research, Vol. 36, No. 11, 01.11.2012, p. 1410-1416.

Research output: Contribution to journalArticle

Thudium, Karen E. ; Ghoshal, Sampa ; Fetterly, Gerald J. ; Haese, Jason P Den ; Karpf, Adam R ; Wetzler, Meir. / Synergism between clofarabine and decitabine through p53R2 : A pharmacodynamic drug-drug interaction modeling. In: Leukemia Research. 2012 ; Vol. 36, No. 11. pp. 1410-1416.
@article{3c6d62202f8f41caa0f968c7a8dba63e,
title = "Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling",
abstract = "Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.",
keywords = "AML, Clofarabine, Decitabine, Pharmacodynamic modeling, Synergy",
author = "Thudium, {Karen E.} and Sampa Ghoshal and Fetterly, {Gerald J.} and Haese, {Jason P Den} and Karpf, {Adam R} and Meir Wetzler",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2012.07.015",
language = "English (US)",
volume = "36",
pages = "1410--1416",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Synergism between clofarabine and decitabine through p53R2

T2 - A pharmacodynamic drug-drug interaction modeling

AU - Thudium, Karen E.

AU - Ghoshal, Sampa

AU - Fetterly, Gerald J.

AU - Haese, Jason P Den

AU - Karpf, Adam R

AU - Wetzler, Meir

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.

AB - Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the interaction between CLO and DEC on an AML cell line and down-regulated p53R2 protein to understand its role. These results confirm a role for p53R2 in both CLO and DEC mechanism of action, demonstrate synergism between these two drugs in this AML model and support the use of this combination in a future clinical trial.

KW - AML

KW - Clofarabine

KW - Decitabine

KW - Pharmacodynamic modeling

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=84866316783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866316783&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.07.015

DO - 10.1016/j.leukres.2012.07.015

M3 - Article

VL - 36

SP - 1410

EP - 1416

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -